nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCB1—peripheral nervous system neoplasm	0.188	1	CbGaD
Ponatinib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0491	0.117	CbGbCtD
Ponatinib—ABCB11—Vincristine—peripheral nervous system neoplasm	0.0441	0.105	CbGbCtD
Ponatinib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.034	0.081	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—peripheral nervous system neoplasm	0.0276	0.0656	CbGbCtD
Ponatinib—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0253	0.0602	CbGbCtD
Ponatinib—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0243	0.0579	CbGbCtD
Ponatinib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.021	0.0499	CbGbCtD
Ponatinib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0195	0.0465	CbGbCtD
Ponatinib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0192	0.0457	CbGbCtD
Ponatinib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0177	0.0421	CbGbCtD
Ponatinib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0177	0.0421	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0131	0.0312	CbGbCtD
Ponatinib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0123	0.0292	CbGbCtD
Ponatinib—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0116	0.0276	CbGbCtD
Ponatinib—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0106	0.0253	CbGbCtD
Ponatinib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0106	0.0253	CbGbCtD
Ponatinib—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.0102	0.0244	CbGbCtD
Ponatinib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00986	0.0235	CbGbCtD
Ponatinib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00756	0.018	CbGbCtD
Ponatinib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00705	0.0168	CbGbCtD
Ponatinib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00693	0.0165	CbGbCtD
Ponatinib—FGFR3—skull—peripheral nervous system neoplasm	0.00543	0.184	CbGeAlD
Ponatinib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00472	0.0112	CbGbCtD
Ponatinib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00453	0.0108	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00445	0.0106	CbGbCtD
Ponatinib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00415	0.00988	CbGbCtD
Ponatinib—FGFR2—skull—peripheral nervous system neoplasm	0.00356	0.12	CbGeAlD
Ponatinib—Imatinib—NTRK1—peripheral nervous system neoplasm	0.00301	0.764	CrCbGaD
Ponatinib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00283	0.00674	CbGbCtD
Ponatinib—FGFR4—brainstem—peripheral nervous system neoplasm	0.0018	0.0608	CbGeAlD
Ponatinib—FGFR4—Podofilox—Etoposide—peripheral nervous system neoplasm	0.00175	0.416	CbGdCrCtD
Ponatinib—FGFR4—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.00121	0.286	CbGdCrCtD
Ponatinib—BCR—trigeminal ganglion—peripheral nervous system neoplasm	0.0012	0.0406	CbGeAlD
Ponatinib—BCR—parotid gland—peripheral nervous system neoplasm	0.00113	0.0383	CbGeAlD
Ponatinib—FGFR1—trigeminal ganglion—peripheral nervous system neoplasm	0.00107	0.0361	CbGeAlD
Ponatinib—RET—trigeminal ganglion—peripheral nervous system neoplasm	0.000957	0.0323	CbGeAlD
Ponatinib—LCK—trigeminal ganglion—peripheral nervous system neoplasm	0.000957	0.0323	CbGeAlD
Ponatinib—FGFR4—cerebellum—peripheral nervous system neoplasm	0.000888	0.03	CbGeAlD
Ponatinib—TEK—trigeminal ganglion—peripheral nervous system neoplasm	0.000871	0.0294	CbGeAlD
Ponatinib—FGFR2—brainstem—peripheral nervous system neoplasm	0.000804	0.0272	CbGeAlD
Ponatinib—KDR—trigeminal ganglion—peripheral nervous system neoplasm	0.000712	0.0241	CbGeAlD
Ponatinib—KDR—parotid gland—peripheral nervous system neoplasm	0.000672	0.0227	CbGeAlD
Ponatinib—KIT—trigeminal ganglion—peripheral nervous system neoplasm	0.000631	0.0213	CbGeAlD
Ponatinib—FGFR3—cerebellum—peripheral nervous system neoplasm	0.000606	0.0205	CbGeAlD
Ponatinib—KIT—parotid gland—peripheral nervous system neoplasm	0.000595	0.0201	CbGeAlD
Ponatinib—KIT—brainstem—peripheral nervous system neoplasm	0.000559	0.0189	CbGeAlD
Ponatinib—ABL1—trigeminal ganglion—peripheral nervous system neoplasm	0.000549	0.0186	CbGeAlD
Ponatinib—BCR—cerebellum—peripheral nervous system neoplasm	0.000524	0.0177	CbGeAlD
Ponatinib—FLT3—cerebellum—peripheral nervous system neoplasm	0.000521	0.0176	CbGeAlD
Ponatinib—ABL1—parotid gland—peripheral nervous system neoplasm	0.000518	0.0175	CbGeAlD
Ponatinib—Nilotinib—ABCB1—peripheral nervous system neoplasm	0.000506	0.128	CrCbGaD
Ponatinib—ABL1—brainstem—peripheral nervous system neoplasm	0.000486	0.0164	CbGeAlD
Ponatinib—FGFR1—cerebellum—peripheral nervous system neoplasm	0.000466	0.0158	CbGeAlD
Ponatinib—Imatinib—ABCB1—peripheral nervous system neoplasm	0.000422	0.107	CrCbGaD
Ponatinib—RET—cerebellum—peripheral nervous system neoplasm	0.000417	0.0141	CbGeAlD
Ponatinib—FGFR2—cerebellum—peripheral nervous system neoplasm	0.000397	0.0134	CbGeAlD
Ponatinib—TEK—cerebellum—peripheral nervous system neoplasm	0.00038	0.0128	CbGeAlD
Ponatinib—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.000346	0.0117	CbGeAlD
Ponatinib—PDGFRA—cerebellum—peripheral nervous system neoplasm	0.000344	0.0116	CbGeAlD
Ponatinib—SRC—cerebellum—peripheral nervous system neoplasm	0.000338	0.0114	CbGeAlD
Ponatinib—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000327	0.011	CbGeAlD
Ponatinib—KDR—cerebellum—peripheral nervous system neoplasm	0.000311	0.0105	CbGeAlD
Ponatinib—KIT—cerebellum—peripheral nervous system neoplasm	0.000275	0.0093	CbGeAlD
Ponatinib—ABL1—cerebellum—peripheral nervous system neoplasm	0.00024	0.0081	CbGeAlD
Ponatinib—ABL1—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000218	0.0517	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000218	0.0517	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000218	0.0517	CbGdCrCtD
Ponatinib—CYP2D6—brainstem—peripheral nervous system neoplasm	0.00021	0.0071	CbGeAlD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.0478	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.0478	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.0478	CbGdCrCtD
Ponatinib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000171	0.00577	CbGeAlD
Ponatinib—ABCG2—cerebellum—peripheral nervous system neoplasm	0.000151	0.00511	CbGeAlD
Ponatinib—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000104	0.0035	CbGeAlD
Ponatinib—Rash—Isotretinoin—peripheral nervous system neoplasm	9.75e-05	0.000498	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	9.75e-05	0.000498	CcSEcCtD
Ponatinib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	9.74e-05	0.000497	CcSEcCtD
Ponatinib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	9.74e-05	0.000497	CcSEcCtD
Ponatinib—Fatigue—Vincristine—peripheral nervous system neoplasm	9.74e-05	0.000497	CcSEcCtD
Ponatinib—Vomiting—Melphalan—peripheral nervous system neoplasm	9.7e-05	0.000495	CcSEcCtD
Ponatinib—Dehydration—Epirubicin—peripheral nervous system neoplasm	9.7e-05	0.000495	CcSEcCtD
Ponatinib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	9.7e-05	0.000495	CcSEcCtD
Ponatinib—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	9.69e-05	0.000495	CcSEcCtD
Ponatinib—Headache—Tretinoin—peripheral nervous system neoplasm	9.69e-05	0.000495	CcSEcCtD
Ponatinib—Headache—Isotretinoin—peripheral nervous system neoplasm	9.69e-05	0.000495	CcSEcCtD
Ponatinib—Hypertension—Etoposide—peripheral nervous system neoplasm	9.68e-05	0.000494	CcSEcCtD
Ponatinib—Pain—Vincristine—peripheral nervous system neoplasm	9.66e-05	0.000493	CcSEcCtD
Ponatinib—Constipation—Vincristine—peripheral nervous system neoplasm	9.66e-05	0.000493	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	9.65e-05	0.000493	CcSEcCtD
Ponatinib—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	9.65e-05	0.000493	CcSEcCtD
Ponatinib—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	9.65e-05	0.000493	CcSEcCtD
Ponatinib—Rash—Melphalan—peripheral nervous system neoplasm	9.62e-05	0.000491	CcSEcCtD
Ponatinib—Dermatitis—Melphalan—peripheral nervous system neoplasm	9.62e-05	0.000491	CcSEcCtD
Ponatinib—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	9.58e-05	0.000489	CcSEcCtD
Ponatinib—Dry skin—Epirubicin—peripheral nervous system neoplasm	9.56e-05	0.000488	CcSEcCtD
Ponatinib—Migraine—Doxorubicin—peripheral nervous system neoplasm	9.5e-05	0.000485	CcSEcCtD
Ponatinib—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	9.5e-05	0.000485	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	9.48e-05	0.000484	CcSEcCtD
Ponatinib—Breast disorder—Epirubicin—peripheral nervous system neoplasm	9.43e-05	0.000481	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	9.4e-05	0.00048	CcSEcCtD
Ponatinib—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	9.33e-05	0.000476	CcSEcCtD
Ponatinib—Face oedema—Doxorubicin—peripheral nervous system neoplasm	9.32e-05	0.000476	CcSEcCtD
Ponatinib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	9.26e-05	0.000473	CcSEcCtD
Ponatinib—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	9.26e-05	0.000473	CcSEcCtD
Ponatinib—Nausea—Topotecan—peripheral nervous system neoplasm	9.26e-05	0.000473	CcSEcCtD
Ponatinib—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	9.23e-05	0.000471	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	9.2e-05	0.00047	CcSEcCtD
Ponatinib—Nausea—Tretinoin—peripheral nervous system neoplasm	9.19e-05	0.000469	CcSEcCtD
Ponatinib—Nausea—Isotretinoin—peripheral nervous system neoplasm	9.19e-05	0.000469	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	9.1e-05	0.000464	CcSEcCtD
Ponatinib—Infection—Etoposide—peripheral nervous system neoplasm	9.09e-05	0.000464	CcSEcCtD
Ponatinib—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	9.08e-05	0.000463	CcSEcCtD
Ponatinib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	9.07e-05	0.000463	CcSEcCtD
Ponatinib—Nausea—Melphalan—peripheral nervous system neoplasm	9.07e-05	0.000463	CcSEcCtD
Ponatinib—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	9.04e-05	0.000462	CcSEcCtD
Ponatinib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	8.98e-05	0.000458	CcSEcCtD
Ponatinib—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	8.97e-05	0.000458	CcSEcCtD
Ponatinib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	8.96e-05	0.000457	CcSEcCtD
Ponatinib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	8.93e-05	0.000456	CcSEcCtD
Ponatinib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	8.93e-05	0.000456	CcSEcCtD
Ponatinib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	8.9e-05	0.000454	CcSEcCtD
Ponatinib—Skin disorder—Etoposide—peripheral nervous system neoplasm	8.89e-05	0.000454	CcSEcCtD
Ponatinib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	8.85e-05	0.000452	CcSEcCtD
Ponatinib—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	8.84e-05	0.000451	CcSEcCtD
Ponatinib—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	8.84e-05	0.000451	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	8.79e-05	0.000449	CcSEcCtD
Ponatinib—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	8.78e-05	0.000448	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	8.72e-05	0.000445	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	8.69e-05	0.000444	CcSEcCtD
Ponatinib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	8.68e-05	0.000443	CcSEcCtD
Ponatinib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	8.65e-05	0.000442	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	8.63e-05	0.000441	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	8.62e-05	0.00044	CcSEcCtD
Ponatinib—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	8.56e-05	0.000437	CcSEcCtD
Ponatinib—Pain—Cisplatin—peripheral nervous system neoplasm	8.54e-05	0.000436	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	8.51e-05	0.000435	CcSEcCtD
Ponatinib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	8.43e-05	0.00043	CcSEcCtD
Ponatinib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	8.41e-05	0.000429	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	8.4e-05	0.000429	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	8.38e-05	0.000428	CcSEcCtD
Ponatinib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	8.29e-05	0.000423	CcSEcCtD
Ponatinib—Paraesthesia—Etoposide—peripheral nervous system neoplasm	8.21e-05	0.000419	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	8.18e-05	0.000418	CcSEcCtD
Ponatinib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	8.16e-05	0.000416	CcSEcCtD
Ponatinib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	8.16e-05	0.000416	CcSEcCtD
Ponatinib—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	8.13e-05	0.000415	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	8.13e-05	0.000415	CcSEcCtD
Ponatinib—Asthenia—Vincristine—peripheral nervous system neoplasm	8.1e-05	0.000414	CcSEcCtD
Ponatinib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	8.09e-05	0.000413	CcSEcCtD
Ponatinib—Infestation—Epirubicin—peripheral nervous system neoplasm	8.04e-05	0.00041	CcSEcCtD
Ponatinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	8.04e-05	0.00041	CcSEcCtD
Ponatinib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	8.04e-05	0.00041	CcSEcCtD
Ponatinib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	8.02e-05	0.000409	CcSEcCtD
Ponatinib—Rash—Dactinomycin—peripheral nervous system neoplasm	7.97e-05	0.000407	CcSEcCtD
Ponatinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	7.95e-05	0.000406	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	7.92e-05	0.000405	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	7.9e-05	0.000403	CcSEcCtD
Ponatinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	7.89e-05	0.000403	CcSEcCtD
Ponatinib—Fatigue—Etoposide—peripheral nervous system neoplasm	7.89e-05	0.000403	CcSEcCtD
Ponatinib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	7.88e-05	0.000402	CcSEcCtD
Ponatinib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	7.84e-05	0.0004	CcSEcCtD
Ponatinib—Jaundice—Epirubicin—peripheral nervous system neoplasm	7.84e-05	0.0004	CcSEcCtD
Ponatinib—Constipation—Etoposide—peripheral nervous system neoplasm	7.82e-05	0.000399	CcSEcCtD
Ponatinib—Pain—Etoposide—peripheral nervous system neoplasm	7.82e-05	0.000399	CcSEcCtD
Ponatinib—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	7.82e-05	0.000399	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	7.8e-05	0.000398	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	7.75e-05	0.000396	CcSEcCtD
Ponatinib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	7.75e-05	0.000396	CcSEcCtD
Ponatinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	7.73e-05	0.000394	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	7.6e-05	0.000388	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	7.58e-05	0.000387	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	7.55e-05	0.000385	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	7.53e-05	0.000384	CcSEcCtD
Ponatinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	7.51e-05	0.000383	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	7.48e-05	0.000382	CcSEcCtD
Ponatinib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	7.48e-05	0.000382	CcSEcCtD
Ponatinib—Dizziness—Vincristine—peripheral nervous system neoplasm	7.47e-05	0.000381	CcSEcCtD
Ponatinib—ABCB1—cerebellum—peripheral nervous system neoplasm	7.45e-05	0.00252	CbGeAlD
Ponatinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	7.45e-05	0.00038	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	7.44e-05	0.00038	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	7.44e-05	0.00038	CcSEcCtD
Ponatinib—Rash—Alitretinoin—peripheral nervous system neoplasm	7.39e-05	0.000377	CcSEcCtD
Ponatinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	7.38e-05	0.000377	CcSEcCtD
Ponatinib—Headache—Alitretinoin—peripheral nervous system neoplasm	7.34e-05	0.000375	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	7.29e-05	0.000372	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	7.25e-05	0.00037	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—peripheral nervous system neoplasm	7.25e-05	0.00037	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	7.25e-05	0.00037	CcSEcCtD
Ponatinib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	7.23e-05	0.000369	CcSEcCtD
Ponatinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	7.23e-05	0.000369	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	7.23e-05	0.000369	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	7.22e-05	0.000368	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	7.18e-05	0.000367	CcSEcCtD
Ponatinib—Vomiting—Vincristine—peripheral nervous system neoplasm	7.18e-05	0.000367	CcSEcCtD
Ponatinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	7.16e-05	0.000366	CcSEcCtD
Ponatinib—Rash—Vincristine—peripheral nervous system neoplasm	7.12e-05	0.000364	CcSEcCtD
Ponatinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	7.11e-05	0.000363	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	7.11e-05	0.000363	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	7.09e-05	0.000362	CcSEcCtD
Ponatinib—Headache—Vincristine—peripheral nervous system neoplasm	7.07e-05	0.000361	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	7.04e-05	0.000359	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	7.02e-05	0.000358	CcSEcCtD
Ponatinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	6.96e-05	0.000355	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—peripheral nervous system neoplasm	6.96e-05	0.000355	CcSEcCtD
Ponatinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	6.83e-05	0.000349	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	6.75e-05	0.000344	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	6.71e-05	0.000343	CcSEcCtD
Ponatinib—Nausea—Vincristine—peripheral nervous system neoplasm	6.71e-05	0.000342	CcSEcCtD
Ponatinib—Flushing—Epirubicin—peripheral nervous system neoplasm	6.7e-05	0.000342	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	6.7e-05	0.000342	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	6.68e-05	0.000341	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	6.64e-05	0.000339	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	6.58e-05	0.000336	CcSEcCtD
Ponatinib—Asthenia—Etoposide—peripheral nervous system neoplasm	6.56e-05	0.000335	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	6.56e-05	0.000335	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	6.55e-05	0.000334	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	6.5e-05	0.000332	CcSEcCtD
Ponatinib—Chills—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000331	CcSEcCtD
Ponatinib—Pruritus—Etoposide—peripheral nervous system neoplasm	6.47e-05	0.00033	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	6.45e-05	0.000329	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	6.44e-05	0.000329	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—peripheral nervous system neoplasm	6.38e-05	0.000326	CcSEcCtD
Ponatinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	6.35e-05	0.000324	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	6.32e-05	0.000323	CcSEcCtD
Ponatinib—Rash—Cisplatin—peripheral nervous system neoplasm	6.3e-05	0.000321	CcSEcCtD
Ponatinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	6.29e-05	0.000321	CcSEcCtD
Ponatinib—Erythema—Epirubicin—peripheral nervous system neoplasm	6.28e-05	0.000321	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	6.28e-05	0.000321	CcSEcCtD
Ponatinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	6.26e-05	0.00032	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	6.24e-05	0.000319	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—peripheral nervous system neoplasm	6.2e-05	0.000316	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	6.2e-05	0.000316	CcSEcCtD
Ponatinib—Back pain—Epirubicin—peripheral nervous system neoplasm	6.08e-05	0.00031	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	6.06e-05	0.000309	CcSEcCtD
Ponatinib—Dizziness—Etoposide—peripheral nervous system neoplasm	6.05e-05	0.000309	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	6.04e-05	0.000308	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.000307	CcSEcCtD
Ponatinib—Chills—Doxorubicin—peripheral nervous system neoplasm	5.99e-05	0.000306	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	5.97e-05	0.000305	CcSEcCtD
Ponatinib—Nausea—Cisplatin—peripheral nervous system neoplasm	5.93e-05	0.000303	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—peripheral nervous system neoplasm	5.92e-05	0.000302	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	5.9e-05	0.000301	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	5.85e-05	0.000299	CcSEcCtD
Ponatinib—Vomiting—Etoposide—peripheral nervous system neoplasm	5.82e-05	0.000297	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	5.81e-05	0.000297	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—peripheral nervous system neoplasm	5.81e-05	0.000297	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—peripheral nervous system neoplasm	5.81e-05	0.000296	CcSEcCtD
Ponatinib—Rash—Etoposide—peripheral nervous system neoplasm	5.77e-05	0.000294	CcSEcCtD
Ponatinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	5.76e-05	0.000294	CcSEcCtD
Ponatinib—Headache—Etoposide—peripheral nervous system neoplasm	5.73e-05	0.000293	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	5.62e-05	0.000287	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—peripheral nervous system neoplasm	5.62e-05	0.000287	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	5.59e-05	0.000285	CcSEcCtD
Ponatinib—Cough—Epirubicin—peripheral nervous system neoplasm	5.48e-05	0.00028	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	5.48e-05	0.00028	CcSEcCtD
Ponatinib—Nausea—Etoposide—peripheral nervous system neoplasm	5.43e-05	0.000277	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—peripheral nervous system neoplasm	5.42e-05	0.000277	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	5.37e-05	0.000274	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	5.35e-05	0.000273	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—peripheral nervous system neoplasm	5.35e-05	0.000273	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	5.31e-05	0.000271	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	5.23e-05	0.000267	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	5.2e-05	0.000266	CcSEcCtD
Ponatinib—Oedema—Epirubicin—peripheral nervous system neoplasm	5.13e-05	0.000262	CcSEcCtD
Ponatinib—Infection—Epirubicin—peripheral nervous system neoplasm	5.09e-05	0.00026	CcSEcCtD
Ponatinib—Cough—Doxorubicin—peripheral nervous system neoplasm	5.07e-05	0.000259	CcSEcCtD
Ponatinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	5.03e-05	0.000257	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	5.02e-05	0.000256	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	5.02e-05	0.000256	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	4.98e-05	0.000254	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	4.96e-05	0.000253	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	4.95e-05	0.000253	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	4.95e-05	0.000253	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	4.92e-05	0.000251	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	4.84e-05	0.000247	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—peripheral nervous system neoplasm	4.74e-05	0.000242	CcSEcCtD
Ponatinib—Infection—Doxorubicin—peripheral nervous system neoplasm	4.71e-05	0.000241	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.000239	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	4.65e-05	0.000238	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	4.65e-05	0.000237	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—peripheral nervous system neoplasm	4.64e-05	0.000237	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	4.61e-05	0.000235	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	4.6e-05	0.000235	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	4.59e-05	0.000234	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	4.57e-05	0.000233	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	4.51e-05	0.00023	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	4.46e-05	0.000228	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	4.43e-05	0.000226	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	4.42e-05	0.000226	CcSEcCtD
Ponatinib—Pain—Epirubicin—peripheral nervous system neoplasm	4.39e-05	0.000224	CcSEcCtD
Ponatinib—Constipation—Epirubicin—peripheral nervous system neoplasm	4.39e-05	0.000224	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000221	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	4.29e-05	0.000219	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	4.26e-05	0.000218	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	4.23e-05	0.000216	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	4.19e-05	0.000214	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	4.18e-05	0.000213	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	4.12e-05	0.000211	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.1e-05	0.000209	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	4.09e-05	0.000209	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.000207	CcSEcCtD
Ponatinib—Pain—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.000207	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	4.05e-05	0.000207	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	4.05e-05	0.000207	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	3.88e-05	0.000198	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	3.75e-05	0.000191	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	3.75e-05	0.000191	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	3.68e-05	0.000188	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	3.63e-05	0.000185	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	3.51e-05	0.000179	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.4e-05	0.000174	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—peripheral nervous system neoplasm	3.39e-05	0.000173	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	3.36e-05	0.000171	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.26e-05	0.000166	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.25e-05	0.000166	CcSEcCtD
Ponatinib—Rash—Epirubicin—peripheral nervous system neoplasm	3.23e-05	0.000165	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.23e-05	0.000165	CcSEcCtD
Ponatinib—Headache—Epirubicin—peripheral nervous system neoplasm	3.21e-05	0.000164	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	3.14e-05	0.00016	CcSEcCtD
Ponatinib—Nausea—Epirubicin—peripheral nervous system neoplasm	3.05e-05	0.000156	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.02e-05	0.000154	CcSEcCtD
Ponatinib—Rash—Doxorubicin—peripheral nervous system neoplasm	2.99e-05	0.000153	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.99e-05	0.000153	CcSEcCtD
Ponatinib—Headache—Doxorubicin—peripheral nervous system neoplasm	2.97e-05	0.000152	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.82e-05	0.000144	CcSEcCtD
Ponatinib—FGFR3—Disease—MYC—peripheral nervous system neoplasm	9.02e-06	5.71e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.91e-06	5.64e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.9e-06	5.63e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	8.88e-06	5.62e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—ERBB2—peripheral nervous system neoplasm	8.83e-06	5.59e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—ERBB2—peripheral nervous system neoplasm	8.81e-06	5.58e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—ERBB2—peripheral nervous system neoplasm	8.75e-06	5.54e-05	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	8.7e-06	5.5e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	8.69e-06	5.5e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—peripheral nervous system neoplasm	8.63e-06	5.46e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—ERBB2—peripheral nervous system neoplasm	8.59e-06	5.44e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—peripheral nervous system neoplasm	8.59e-06	5.43e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KNG1—peripheral nervous system neoplasm	8.58e-06	5.43e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—HRAS—peripheral nervous system neoplasm	8.55e-06	5.41e-05	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	8.54e-06	5.41e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.54e-06	5.4e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	8.53e-06	5.4e-05	CbGpPWpGaD
Ponatinib—FGFR4—Disease—AKT1—peripheral nervous system neoplasm	8.45e-06	5.35e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.44e-06	5.34e-05	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—AKT1—peripheral nervous system neoplasm	8.44e-06	5.34e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.42e-06	5.33e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—HRAS—peripheral nervous system neoplasm	8.41e-06	5.32e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.4e-06	5.32e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—HRAS—peripheral nervous system neoplasm	8.37e-06	5.3e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—AKT1—peripheral nervous system neoplasm	8.34e-06	5.28e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—NRAS—peripheral nervous system neoplasm	8.34e-06	5.28e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—NRAS—peripheral nervous system neoplasm	8.32e-06	5.27e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	8.31e-06	5.26e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—HRAS—peripheral nervous system neoplasm	8.25e-06	5.22e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—HRAS—peripheral nervous system neoplasm	8.21e-06	5.2e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—NRAS—peripheral nervous system neoplasm	8.18e-06	5.18e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	8.17e-06	5.17e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—ERBB2—peripheral nervous system neoplasm	8.16e-06	5.16e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—ERBB2—peripheral nervous system neoplasm	8.14e-06	5.15e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	8.11e-06	5.13e-05	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	8.11e-06	5.13e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.09e-06	5.12e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	8.09e-06	5.12e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	8.07e-06	5.11e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PTPN11—peripheral nervous system neoplasm	8.06e-06	5.1e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—AKT1—peripheral nervous system neoplasm	8e-06	5.06e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	7.99e-06	5.06e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.85e-06	4.97e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—ERBB2—peripheral nervous system neoplasm	7.77e-06	4.92e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.76e-06	4.91e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.75e-06	4.91e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.74e-06	4.9e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—ERBB2—peripheral nervous system neoplasm	7.74e-06	4.9e-05	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.68e-06	4.86e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—HRAS—peripheral nervous system neoplasm	7.67e-06	4.85e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	7.63e-06	4.83e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.62e-06	4.82e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.59e-06	4.8e-05	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.54e-06	4.77e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—GNAS—peripheral nervous system neoplasm	7.5e-06	4.75e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.45e-06	4.72e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTPN11—peripheral nervous system neoplasm	7.44e-06	4.71e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.44e-06	4.71e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—HRAS—peripheral nervous system neoplasm	7.43e-06	4.7e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—AKT1—peripheral nervous system neoplasm	7.43e-06	4.7e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—HRAS—peripheral nervous system neoplasm	7.39e-06	4.68e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—AKT1—peripheral nervous system neoplasm	7.39e-06	4.68e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—NRAS—peripheral nervous system neoplasm	7.37e-06	4.66e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	7.37e-06	4.66e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—AKT1—peripheral nervous system neoplasm	7.28e-06	4.61e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—AKT1—peripheral nervous system neoplasm	7.25e-06	4.59e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	7.24e-06	4.58e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	7.24e-06	4.58e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.23e-06	4.57e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—NRAS—peripheral nervous system neoplasm	7.21e-06	4.56e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.21e-06	4.56e-05	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.16e-06	4.53e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.14e-06	4.52e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PTPN11—peripheral nervous system neoplasm	7.14e-06	4.52e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	7.13e-06	4.51e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—NRAS—peripheral nervous system neoplasm	7.08e-06	4.48e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—HRAS—peripheral nervous system neoplasm	7.08e-06	4.48e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	7.07e-06	4.48e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—peripheral nervous system neoplasm	7.07e-06	4.47e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	7.06e-06	4.47e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.05e-06	4.46e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	7.02e-06	4.45e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.01e-06	4.44e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	6.83e-06	4.32e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	6.82e-06	4.31e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	6.8e-06	4.3e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.78e-06	4.29e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—AKT1—peripheral nervous system neoplasm	6.77e-06	4.29e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—HRAS—peripheral nervous system neoplasm	6.76e-06	4.28e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—NRAS—peripheral nervous system neoplasm	6.72e-06	4.25e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.7e-06	4.24e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—NRAS—peripheral nervous system neoplasm	6.7e-06	4.24e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.7e-06	4.24e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—NRAS—peripheral nervous system neoplasm	6.66e-06	4.21e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.64e-06	4.2e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	6.6e-06	4.18e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTPN11—peripheral nervous system neoplasm	6.59e-06	4.17e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—AKT1—peripheral nervous system neoplasm	6.56e-06	4.15e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—NRAS—peripheral nervous system neoplasm	6.54e-06	4.14e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—AKT1—peripheral nervous system neoplasm	6.53e-06	4.13e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—ERBB2—peripheral nervous system neoplasm	6.37e-06	4.03e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.36e-06	4.02e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.31e-06	4e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	6.3e-06	3.99e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—peripheral nervous system neoplasm	6.26e-06	3.96e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—AKT1—peripheral nervous system neoplasm	6.25e-06	3.96e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	6.23e-06	3.94e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—NRAS—peripheral nervous system neoplasm	6.21e-06	3.93e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—MYC—peripheral nervous system neoplasm	6.2e-06	3.92e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—NRAS—peripheral nervous system neoplasm	6.19e-06	3.92e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.13e-06	3.88e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	6.12e-06	3.87e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	6.11e-06	3.87e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—HRAS—peripheral nervous system neoplasm	6.1e-06	3.86e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—MYC—peripheral nervous system neoplasm	6.09e-06	3.85e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—HRAS—peripheral nervous system neoplasm	6.09e-06	3.85e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.02e-06	3.81e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—HRAS—peripheral nervous system neoplasm	5.99e-06	3.79e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—AKT1—peripheral nervous system neoplasm	5.97e-06	3.78e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.92e-06	3.75e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—NRAS—peripheral nervous system neoplasm	5.91e-06	3.74e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.91e-06	3.74e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—NRAS—peripheral nervous system neoplasm	5.89e-06	3.72e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—ERBB2—peripheral nervous system neoplasm	5.88e-06	3.72e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.85e-06	3.7e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.84e-06	3.69e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MYC—peripheral nervous system neoplasm	5.78e-06	3.66e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	5.77e-06	3.65e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MYC—peripheral nervous system neoplasm	5.77e-06	3.65e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	5.75e-06	3.64e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.71e-06	3.61e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.7e-06	3.61e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ERBB2—peripheral nervous system neoplasm	5.64e-06	3.57e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.56e-06	3.52e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.5e-06	3.48e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.5e-06	3.48e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.46e-06	3.46e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	5.42e-06	3.43e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	5.39e-06	3.41e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.39e-06	3.41e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—AKT1—peripheral nervous system neoplasm	5.39e-06	3.41e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.38e-06	3.4e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	5.29e-06	3.35e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—AKT1—peripheral nervous system neoplasm	5.29e-06	3.35e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HRAS—peripheral nervous system neoplasm	5.28e-06	3.34e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.21e-06	3.3e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ERBB2—peripheral nervous system neoplasm	5.21e-06	3.3e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.19e-06	3.28e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.18e-06	3.28e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—HRAS—peripheral nervous system neoplasm	5.18e-06	3.28e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.18e-06	3.28e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.17e-06	3.27e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.16e-06	3.27e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.03e-06	3.18e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.96e-06	3.14e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—peripheral nervous system neoplasm	4.92e-06	3.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—peripheral nervous system neoplasm	4.9e-06	3.1e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—peripheral nervous system neoplasm	4.87e-06	3.08e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NRAS—peripheral nervous system neoplasm	4.85e-06	3.07e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—peripheral nervous system neoplasm	4.78e-06	3.03e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.76e-06	3.01e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	4.7e-06	2.97e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.66e-06	2.95e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—peripheral nervous system neoplasm	4.66e-06	2.95e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.61e-06	2.92e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.58e-06	2.9e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—peripheral nervous system neoplasm	4.57e-06	2.9e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.57e-06	2.89e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.56e-06	2.89e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—peripheral nervous system neoplasm	4.54e-06	2.87e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—peripheral nervous system neoplasm	4.53e-06	2.87e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.52e-06	2.86e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NRAS—peripheral nervous system neoplasm	4.47e-06	2.83e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	4.46e-06	2.82e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	4.43e-06	2.8e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.38e-06	2.77e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.35e-06	2.75e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	4.34e-06	2.75e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.34e-06	2.75e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—peripheral nervous system neoplasm	4.34e-06	2.75e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.33e-06	2.74e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—peripheral nervous system neoplasm	4.33e-06	2.74e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—peripheral nervous system neoplasm	4.33e-06	2.74e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.32e-06	2.73e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—peripheral nervous system neoplasm	4.31e-06	2.73e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—peripheral nervous system neoplasm	4.3e-06	2.72e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—peripheral nervous system neoplasm	4.29e-06	2.72e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.27e-06	2.7e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—peripheral nervous system neoplasm	4.22e-06	2.67e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—peripheral nervous system neoplasm	4.17e-06	2.64e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.12e-06	2.61e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.05e-06	2.56e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.04e-06	2.56e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—peripheral nervous system neoplasm	4.01e-06	2.54e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—peripheral nervous system neoplasm	4e-06	2.53e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—peripheral nervous system neoplasm	3.96e-06	2.51e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.82e-06	2.42e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—peripheral nervous system neoplasm	3.82e-06	2.42e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.81e-06	2.41e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—peripheral nervous system neoplasm	3.8e-06	2.41e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	3.77e-06	2.39e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.74e-06	2.37e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—peripheral nervous system neoplasm	3.69e-06	2.34e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.65e-06	2.31e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.6e-06	2.28e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.57e-06	2.26e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.56e-06	2.25e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—peripheral nervous system neoplasm	3.55e-06	2.25e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—peripheral nervous system neoplasm	3.55e-06	2.24e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	3.55e-06	2.24e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.5e-06	2.22e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.41e-06	2.16e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.35e-06	2.12e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.32e-06	2.1e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.32e-06	2.1e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.31e-06	2.09e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—peripheral nervous system neoplasm	3.27e-06	2.07e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.18e-06	2.01e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.17e-06	2.01e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—peripheral nervous system neoplasm	3.14e-06	1.99e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.13e-06	1.98e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—peripheral nervous system neoplasm	3.13e-06	1.98e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.01e-06	1.91e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.96e-06	1.87e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.92e-06	1.85e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.92e-06	1.85e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—peripheral nervous system neoplasm	2.9e-06	1.83e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	2.89e-06	1.83e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—peripheral nervous system neoplasm	2.89e-06	1.83e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	2.84e-06	1.8e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.81e-06	1.78e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.8e-06	1.77e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.8e-06	1.77e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.77e-06	1.76e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—peripheral nervous system neoplasm	2.77e-06	1.75e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.58e-06	1.64e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—peripheral nervous system neoplasm	2.56e-06	1.62e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.47e-06	1.56e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.4e-06	1.52e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	2.35e-06	1.48e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.29e-06	1.45e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.12e-06	1.34e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.03e-06	1.28e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.02e-06	1.28e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.79e-06	1.13e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	1.68e-06	1.06e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	1.46e-06	9.21e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.27e-06	8.02e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.19e-06	7.56e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	7.81e-07	4.94e-06	CbGpPWpGaD
